New hope for advanced breast cancer: drug combo targets resistant tumors
NCT ID NCT07182721
First seen Nov 01, 2025
Summary
This phase 2 trial tests a combination of two drugs, SKB264 and inetetamab, in 48 people with HER2-positive advanced breast cancer that has worsened after previous treatment. The goal is to see if the combination can shrink tumors or slow the disease. Participants receive the drugs every two weeks at a single center in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB264 (a drug) plus inetetamab (an antibody)
What this could lead to
If it works, this could offer a new treatment option for people with HER2-positive advanced breast cancer who have stopped responding to current therapies.
What could go wrong
This is a small, early-phase trial with only 48 people at one center. It may not work for everyone, and side effects are possible. Success is not guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.